View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
March 24, 2022updated 28 Mar 2022 5:55am

Renal Cell Carcinoma accounts for 2.5% share of global Oncology clinical trial activity in 2021

By Carmen

Renal Cell Carcinoma accounted for a 2.5% share of the global clinical trials within the Oncology therapy area in 2021, registering an increase of 0.3% when compared with the last ten-year average of 2.2% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Industry sponsored trials outnumber non-industry sponsored trials for Renal Cell Carcinoma

Industry sponsored trials held a 71.8% share of all the clinical trials for Renal Cell Carcinoma indication in 2021, registering an increase of 21.2% when compared with the ten-year average of 50.6%. Non-industry sponsored trials accounted for a 28.2% share in 2021, marking a decrease of 21.2% over the ten-year average of 49.4%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top regions of industry sponsored Renal Cell Carcinoma trials

Asia-Pacific was the top region for industry sponsored Renal Cell Carcinoma trials, accounting for a 51.6% share in 2021, when compared with the five-year average of 51.3% and ten-year average of 43.9%.

North America was at the second position with a 41.1% share in 2021, over the five-year average of 58.4% and ten-year average of 64.7%, followed by Europe with a 33.7% share in 2021, as against five-year and ten-year averages of 40.7% and 43.4% respectively.

Middle East and Africa stood fourth with an 11.6% share in 2021, compared with the five-year average of 6.0% and ten-year average of 5.7%, followed by South and Central America with a 6.3% share in 2021, over five-year and ten-year averages of 7.1% and 6.4% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

The US was the top country for industry sponsored Renal Cell Carcinoma trials, accounting for a 41.1% share in 2021, as against the five-year average of 56.9% and ten-year average of 62.8%.

China held a 31.6% share in 2021, over the five-year average of 17.1% and ten-year average of 13.1%, followed by Russia with an 18.9% share in 2021, compared with the five-year and ten-year averages of 14.5% and 10.4% respectively.

Spain held a 14.7% share in 2021, as against the five-year average of 23.4% and ten-year average of 21.8%.

The UK held a 10.5% share in 2021, over the five-year and ten-year averages of 18.5% and 20.0% respectively.

Top regions of non-industry sponsored Renal Cell Carcinoma trials

Asia-Pacific was the top region for non-industry sponsored Renal Cell Carcinoma trials, accounting for a 59.0% share in 2021 when compared with the five-year average of 23.3% and ten-year average of 26.8%.

North America was at the second position with a 28.2% share in 2021, over the five-year and ten-year averages of 50.7% and 44.9% respectively, followed by Europe with a 12.8% share in 2021, as against the five-year average of 25.2% and ten-year average of 27.2%.

Middle East and Africa stood at the fourth position with a 0.0% share in 2021, compared with the five-year average of 0.8% and ten-year average of 0.8%, followed by South and Central America with a 0.0% share in 2021, over the five-year and ten-year averages of 1.2% and 1.1% respectively.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

China was the top country for non-industry sponsored Renal Cell Carcinoma trials, accounting for a 48.7% share in 2021, as against the five-year average of 11.0% and ten-year average of 8.4%.

The US held a 23.1% share in 2021, over the five-year average of 49.1% and ten-year average of 43.0%, followed by Canada with a 5.1% share, compared with the five-year and ten-year averages of 2.3% and 2.9% respectively.

France held a 5.1% share in 2021, as against the five-year average of 6.3% and ten-year average of 6.1%.

Japan held a 5.1% share in 2021, over the five-year average of 7.0% and ten-year average of 12.3%.

Phase I trials lead industry sponsored clinical trials for Renal Cell Carcinoma in 2021

Phase I trials held a 61.8% share of industry sponsored clinical trials for Renal Cell Carcinoma in 2021, over the five-year average of 48.0% and ten-year average of 46.0%.

Phase II trials held a 27.5% share in 2021, as against the five-year average of 34.9% and ten-year average of 35.1%. Phase III trials held a 6.9% share in 2021, compared with the five-year and ten-year averages of 8.1% and 7.1% respectively.

Phase IV trials held a 3.9% share in 2021, over the five-year average of 8.9% and ten-year average of 11.9%.

Phase II trials lead non-industry sponsored clinical trials for Renal Cell Carcinoma in 2021

Phase II trials held a 72.5% share of non-industry sponsored clinical trials for Renal Cell Carcinoma in 2021, over the five-year average of 65.3% and ten-year average of 65.3%.

Phase I trials held a 12.5% share in 2021, as against the five-year average of 19.9% and ten-year average of 19.5%. Phase IV trials held a 12.5% share, compared with the five-year and ten-year averages of 9.5% and 10.4% respectively.

Phase III trials held a 2.5% share in 2021, over the five-year average of 5.4% and ten-year average of 4.8%.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU